Go Pro

McKesson (MCK) Stock Price, News & Analysis

McKesson logo
$857.61 -7.90 (-0.91%)
Closing price 03:59 PM Eastern
Extended Trading
$857.36 -0.25 (-0.03%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About McKesson Stock (NYSE:MCK)

Advanced

Key Stats

Today's Range
$843.72
$863.55
50-Day Range
$735.76
$891.37
52-Week Range
$637.00
$999.00
Volume
773,328 shs
Average Volume
888,733 shs
Market Capitalization
$100.41 billion
P/E Ratio
22.29
Dividend Yield
0.38%
Price Target
$962.67
Consensus Rating
Moderate Buy

Company Overview

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers. McKesson also offers a range of technology and automation solutions — including pharmacy automation, supply chain management software, and analytics — designed to improve operational efficiency, inventory control and patient safety for its customers. In addition, the firm provides support services such as clinical program management, patient access and adherence services for specialty therapies, and commercial services for biopharma manufacturers.

McKesson serves a broad customer base that includes retail and independent pharmacies, long-term care providers, hospitals and health systems, physician offices and specialty clinics. While its operations are concentrated in the United States and Canada, the company works with global pharmaceutical manufacturers and participates in international supply chain activities. Its business model emphasizes integration between distribution, technology and services to support the delivery of medications and related care.

Led by a corporate management team focused on resilience and technology-enabled solutions, McKesson has leveraged its long history in healthcare distribution to prioritize supply chain reliability, digital transformation and expanded services for specialty and complex therapies. The company’s combination of logistics capabilities, service offerings and health-technology products positions it as a key intermediary in the U.S. healthcare system.

AI Generated. May Contain Errors.

McKesson Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
97th Percentile Overall Score

MCK MarketRank™: 

McKesson scored higher than 97% of companies evaluated by MarketBeat, and ranked 10th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    McKesson has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 14 buy ratings, 3 hold ratings, and no sell ratings.

  • Upside Potential

    McKesson has a consensus price target of $962.67, representing about 12.3% upside from its current price of $857.61.

  • Amount of Analyst Coverage

    McKesson has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about McKesson's stock forecast and price target.
  • Earnings Growth

    Earnings for McKesson are expected to grow by 12.83% in the coming year, from $44.28 to $49.96 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of McKesson is 22.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.95.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of McKesson is 22.29, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 281.83.

  • Price to Earnings Growth Ratio

    McKesson has a PEG Ratio of 1.46. PEG Ratios above 1 indicate that a company could be overvalued.

  • Read more about McKesson's valuation and earnings.
  • Percentage of Shares Shorted

    3.31% of the float of McKesson has been sold short.
  • Short Interest Ratio / Days to Cover

    McKesson has a short interest ratio ("days to cover") of 4.12.
  • Change versus previous month

    Short interest in McKesson has recently decreased by 5.82%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    McKesson has a dividend yield of 0.37%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    McKesson has been increasing its dividend for 17 years.

  • Dividend Coverage

    The dividend payout ratio of McKesson is 9.77%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, McKesson will have a dividend payout ratio of 7.53% next year. This indicates that McKesson will be able to sustain or increase its dividend.

  • Read more about McKesson's dividend.
  • News Sentiment

    McKesson has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 48 news articles for McKesson this week, compared to 10 articles on an average week.
  • Search Interest

    29 people have searched for MCK on MarketBeat in the last 30 days. This is an increase of 45% compared to the previous 30 days.
  • MarketBeat Follows

    23 people have added McKesson to their MarketBeat watchlist in the last 30 days. This is an increase of 188% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, McKesson insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,262,035.00 in company stock.

  • Percentage Held by Insiders

    0.06% of the stock of McKesson is held by insiders.

  • Percentage Held by Institutions

    85.07% of the stock of McKesson is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about McKesson's insider trading history.
Receive MCK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for McKesson and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MCK Stock News Headlines

Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
MMSI Q2 Earnings & Revenues Beat Estimates, '26 Guidance Raised
McKesson distribution facility exterior at dusk, showing branded trucks at loading docks and a glass-walled warehouse interior.
McKesson's Compounding Keeps Adding Up
McKesson posted strong fiscal 2026 results, raised guidance, boosted buybacks and its dividend, and maintains a Moderate Buy rating from analysts amid its evolving specialty business mix.
McKesson (NYSE:MCK) CEO Sells 8,463 Shares
See More Headlines

MCK Stock Analysis - Frequently Asked Questions

McKesson's stock was trading at $820.18 at the beginning of the year. Since then, MCK stock has increased by 4.6% and is now trading at $857.6070.

McKesson Corporation (NYSE:MCK) issued its earnings results on Thursday, May, 7th. The company reported $11.69 EPS for the quarter, beating the consensus estimate of $11.56 by $0.13. The business's revenue for the quarter was up 6.0% compared to the same quarter last year.
Read the conference call transcript
.

McKesson subsidiaries include Echo, LloydsDirect, Medical Specialties Distributors, Well.ca, RxCrossroads, CoverMyMeds, HealthQx, and more.

Top institutional investors of McKesson include Handelsbanken Fonder AB (0.14%), Assenagon Asset Management S.A. (0.05%), Wedge Capital Management L L P NC (0.03%) and Czech National Bank (0.03%). Insiders that own company stock include Britt J Vitalone, Brian S Tyler, Michele Lau, Leann B Smith, Thomas L Rodgers, Napoleon B Rutledge Jr, Maria Martinez and Susan R Salka.
View institutional ownership trends
.

Shares of MCK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that McKesson investors own include Comcast (CMCSA), Chevron (CVX), Bristol Myers Squibb (BMY), Charles Schwab (SCHW), Edwards Lifesciences (EW), Yum! Brands (YUM) and Toronto Dominion Bank (TD).

Company Calendar

Last Earnings
5/07/2026
Record date for 7/1 Dividend
6/01/2026
Ex-Dividend for 7/1 Dividend
6/01/2026
Dividend Payable
7/01/2026
Today
7/31/2026
Next Earnings (Estimated)
8/05/2026
Fiscal Year End
3/31/2027

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Distributors
Current Symbol
NYSE:MCK
CIK
927653
Employees
43,000
Year Founded
1833

Price Target and Rating

High Price Target
$1,085.00
Low Price Target
$812.00
Potential Upside/Downside
+12.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
17 Analysts

Profitability

EPS (Trailing Twelve Months)
$38.47
Trailing P/E Ratio
22.29
Forward P/E Ratio
19.37
P/E Growth
1.42
Net Income
$4.76 billion
Net Margins
1.18%
Pretax Margin
1.54%
Return on Equity
-345.35%
Return on Assets
5.85%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.85
Quick Ratio
0.49

Sales & Book Value

Annual Sales
$403.43 billion
Price / Sales
0.25
Cash Flow
$45.16 per share
Price / Cash Flow
18.99
Book Value
($14.51) per share
Price / Book
-59.10

Miscellaneous

Outstanding Shares
117,080,000
Free Float
117,008,000
Market Cap
$100.41 billion
Optionable
Optionable
Beta
0.31

Social Links

10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NYSE:MCK) was last updated on 7/31/2026 by MarketBeat.com Staff.
From Our Partners